{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T11:15:28Z","timestamp":1789730128384,"version":"4.0.1"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T00:00:00Z","timestamp":1782259200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Adropin, an endogenous peptide hormone with established roles in energy homeostasis and endothelial function, has been implicated in metabolic disease and chronic kidney disease. However, its relationship with sarcopenia in diabetic nephropathy (DN), an increasingly recognised complication of type 2 diabetes mellitus (T2DM), remains poorly characterised. We evaluated serum adropin in T2DM patients with and without DN compared with a younger healthy control group (with the age difference acknowledged as a major confounder) and assessed whether adropin levels are associated with sarcopenia indices and total antioxidant status (TAS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This cross-sectional study included 83 participants: 59 patients with T2DM (37 with DN, 21 without DN (1 with missing UACR)) and 24 healthy controls. Sarcopenia evaluation, including body composition by bioelectrical impedance analysis and hand-grip strength using a hand dynamometer, was completed in 31 diabetic patients. Sarcopenia was operationally defined by reduced hand-grip strength according to EWGSOP2 thresholds (&amp;lt;27\u00a0kg for men, &amp;lt;16\u00a0kg for women). Serum adropin was measured by ELISA; TAS and TOS were measured by the Erel colorimetric method.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Serum adropin was significantly lower in T2DM patients than in controls (197.4 \u00b1 129.1 vs 352.3 \u00b1 240.7 pg\/mL, p = 0.011). Within the diabetic cohort, adropin did not differ between DN and non-DN patients (201.4 \u00b1 119.7 vs 193.8 \u00b1 139.1 pg\/mL, p = 0.370; ROC AUC 0.574). In the sarcopenia subgroup (n = 31), hand-grip strength was significantly lower in DN than non-DN patients (1st measurement: 18.7 \u00b1 4.7 vs 26.5 \u00b1 9.5\u00a0kg, p = 0.012; 3rd measurement: 17.8 \u00b1 4.8 vs 25.1 \u00b1 9.1\u00a0kg, p = 0.035), while muscle mass and walking speed did not differ. Patients meeting EWGSOP2 grip criteria for low strength showed numerically lower adropin than non-sarcopenic patients (169.5 \u00b1 73.6 vs 238.9 \u00b1 181.7 pg\/mL, p = 0.358). Adropin correlated strongly with TAS (\u03c1 = 0.82, p &amp;lt; 0.001).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Serum adropin is markedly reduced in T2DM but does not discriminate DN from non-DN patients in this cohort. Reduced hand-grip strength is the most consistent sarcopenia-related abnormality in DN patients, supporting a functional rather than purely anthropometric muscle deficit. The strong positive correlation between adropin and TAS suggests that adropin tracks the broader oxidative-metabolic milieu of T2DM rather than functioning as an independent clinical biomarker for DN or sarcopenia; longitudinal validation is required before any biomarker role can be considered.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1884793","type":"journal-article","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T08:25:01Z","timestamp":1782289501000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Serum adropin levels and their association with sarcopenia in patients with diabetic nephropathy: a cross-sectional study"],"prefix":"10.3389","volume":"17","author":[{"given":"Emel","family":"Tatl\u0131","sequence":"first","affiliation":[{"name":"Department of Nephrology, University of Health Sciences, Gaziosmanpa\u015fa Training and Research Hospital","place":["Istanbul, T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tu\u011fba","family":"Kip","sequence":"additional","affiliation":[{"name":"Independent Researcher","place":["Istanbul, T\u00fcrkiye"]},{"name":"Medical Department, Abdi \u0130brahim Pharmaceuticals","place":["Istanbul, T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"15018","DOI":"10.1038\/nrdp.2015.18","article-title":"Diabetic kidney disease","volume":"1","author":"Thomas","year":"2015","journal-title":"Nat Rev Dis Primers"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s40620-020-00840-y","article-title":"Sarcopenia in chronic kidney disease: what have we learned so far","volume":"34","author":"Sabatino","year":"2021","journal-title":"J Nephrol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfy139","article-title":"Quality over quantity? Association of skeletal muscle myosteatosis and myofibrosis on physical function in chronic kidney disease","volume":"34","author":"Wilkinson","year":"2019","journal-title":"Nephrol Dial Transplant"},{"key":"B4","doi-asserted-by":"publisher","first-page":"98","DOI":"10.5935\/0101-2800.20150014","article-title":"Sarcopenia in chronic kidney disease","volume":"37","author":"Souza","year":"2015","journal-title":"J Bras Nefrol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2008.10.011","article-title":"Identification of adropin as a secreted factor linking dietary macronutrient intake with energy homeostasis and lipid metabolism","volume":"8","author":"Kumar","year":"2008","journal-title":"Cell Metab"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.109.931782","article-title":"Adropin is a novel regulator of endothelial function","volume":"122","author":"Lovren","year":"2010","journal-title":"Circulation"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-2194","article-title":"Low circulating adropin concentrations with obesity and aging correlate with risk factors for metabolic disease and increase after gastric bypass surgery in humans","volume":"97","author":"Butler","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1515\/cclm-2013-0844","article-title":"Low serum adropin is associated with coronary atherosclerosis in type 2 diabetic and non-diabetic patients","volume":"52","author":"Wu","year":"2014","journal-title":"Clin Chem Lab Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2025.1511730","article-title":"Serum adropin levels as a potential biomarker for predicting diabetic kidney disease progression","volume":"16","author":"Chen","year":"2025","journal-title":"Front Endocrinol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.regpep.2014.04.001","article-title":"Serum adropin levels are decreased in patients with acute myocardial infarction","author":"Yu","year":"2014","journal-title":"Regul Pept"},{"key":"B11","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s11010-013-1660-4","article-title":"Expression of adropin in rat brain, cerebellum, kidneys, heart, liver and pancreas in streptozotocin-induced diabetes","volume":"380","author":"Aydin","year":"2013","journal-title":"Mol Cell Biochem"},{"key":"B12","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.peptides.2016.03.009","article-title":"Adropin reduces paracellular permeability of rat brain endothelial cells exposed to ischemia-like conditions","volume":"81","author":"Yang","year":"2016","journal-title":"Peptides"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.2337\/db14-0388","article-title":"Regulation of substrate oxidation preferences in muscle by the peptide hormone adropin","volume":"63","author":"Gao","year":"2014","journal-title":"Diabetes"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1152\/ajpregu.00511.2015","article-title":"Adropin acts in brain to inhibit water drinking: potential interaction with the orphan G protein-coupled receptor, GPR19","volume":"310","author":"Stein","year":"2016","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.4149\/bll_2015_030","article-title":"The bone marrow plays a role in the adropin secretion","volume":"116","author":"Ayd\u0131n","year":"2015","journal-title":"Bratisl Lek Listy"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.4103\/njcp.njcp_780_23","article-title":"Investigation of adropin levels in patients with chronic obstructive pulmonary disease","volume":"27","author":"Ozkan","year":"2024","journal-title":"Niger J Clin Pract"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinbiochem.2003.11.015","article-title":"A novel automated direct measurement method for total antioxidant capacity using a new generation, more stable ABTS radical cation","volume":"37","author":"Erel","year":"2004","journal-title":"Clin Biochem"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinbiochem.2005.08.008","article-title":"A new automated colorimetric method for measuring total oxidant status","volume":"38","author":"Erel","year":"2005","journal-title":"Clin Biochem"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241713541","article-title":"Biomarkers of oxidative stress in diabetes mellitus with diabetic nephropathy complications","volume":"24","author":"Goycheva","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B20","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1093\/ageing\/afy169","article-title":"Sarcopenia: revised European consensus on definition and diagnosis (EWGSOP2)","volume":"48","author":"Cruz-Jentoft","year":"2019","journal-title":"Age Ageing"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.4149\/bll_2016_020","article-title":"Antidiabetic and hypolipidemic effects of adropin in streptozotocin-induced type 2 diabetic rats","volume":"117","author":"Akc\u0131lar","year":"2016","journal-title":"Bratisl Lek Listy"},{"key":"B22","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1053\/j.jrn.2013.01.001","article-title":"Etiology of the protein-energy wasting syndrome in chronic kidney disease: a consensus statement from the International Society of Renal Nutrition and Metabolism (ISRNM)","volume":"23","author":"Carrero","year":"2013","journal-title":"J Ren Nutr"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.10261013","article-title":"Comparative associations of muscle mass and muscle strength with mortality in dialysis patients","volume":"9","author":"Isoyama","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/6038261","article-title":"Association of serum adropin concentrations with diabetic nephropathy","volume":"2016","author":"Hu","year":"2016","journal-title":"Mediators Inflammation"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1159\/000519173","article-title":"The clinical value of serum adropin level in early detection of diabetic nephropathy","volume":"46","author":"Es-haghi","year":"2021","journal-title":"Kidney Blood Press Res"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1884793\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T08:25:01Z","timestamp":1782289501000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1884793\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,24]]},"references-count":25,"alternative-id":["10.3389\/fendo.2026.1884793"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1884793","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,24]]},"article-number":"1884793"}}